Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2968389 | 1.00 | CHRNA7 (0.41) | CHRNA7 | |
| SCHEMBL9459002 | 0.92 | CHRM2 (0.40) | — | |
| Maleic Acid SCHEMBL194353 | 0.88 | CHRNA7 (0.39) | CHRNA7 | |
| Maleic Acid SCHEMBL9854125 | 0.88 | CHRNA7 (0.39) | CHRNA7 | |
| Cadaverine Tartrate SCHEMBL9710670 | 0.87 | CHRNA7 (0.35) | CHRNA7 | |
| Cadaverine Tartrate SCHEMBL9710674 | 0.87 | CHRNA7 (0.35) | CHRNA7 | |
| SCHEMBL8961518 | 0.84 | CHRNA7 (0.41) | CHRNA7 | |
| SCHEMBL9585060 | 0.81 | CHRNA7 (0.41) | CHRNA7 | |
| SCHEMBL9458898 | 0.81 | — | — | |
| SCHEMBL9710931 | 0.81 | CHRNA7 (0.41) | CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0470668-A1 | A process for preparing enantiomers of compounds having muscarinic activity | MERCK SHARP & DOHME LTD. (GB) | 1992-02-12 | — | — | EP | claimed |
| US-5073557-A | Cognition activators, stimulants of central muscarinic acetylc holine receptors | MERCK SHARP & DOHME LIMITED (GB) | 1991-12-17 | — | — | US | claimed |
| EP-0416754-A2 | A novel substituted pyrazine, formulations thereof and use in medicine | MERCK SHARP & DOHME LTD. (GB) | 1991-03-13 | — | — | EP | claimed |
| JP-3135979-A | — | — | None | — | — | JP | disclosed |
| JP-4279584-A | — | — | None | — | — | JP | disclosed |
| US-9707220-B2 | Scopolamine for the treatment of depression and anxiety | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2017-07-18 | — | — | US | disclosed |
| US-20140378501-A1 | SCOPOLAMINE FOR THE TREATMENT OF DEPRESSION AND ANXIETY | The Governmen of the United States of America, as represented by Secretary, Department of Health and (US) | 2014-12-25 | — | — | US | disclosed |
| US-8859585-B2 | Scopolamine for the treatment of depression and anxiety | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2014-10-14 | — | — | US | disclosed |
| EP-1896025-A1 | SCOPOLAMINE FOR THE TREATMENT OF DEPRESSION AND ANXIETY | GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2008-03-12 | — | — | EP | disclosed |
| US-20060270698-A1 | Scopolamine for the treatment of depression and anxiety | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2006-11-30 | — | — | US | disclosed |
| WO-2006127418-A1 | SCOPOLAMINE FOR THE TREATMENT OF DEPRESSION AND ANXIETY | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, NATIONAL INSTITUTES OF HEALTH (US) | 2006-11-30 | — | — | WO | disclosed |
| JP-H04279584-A | PRODUCTION OF ENANTIOMER OF COMPOUND HAVING MUSCARINE ACTIVITY | MERCK SHARP & DOHME LTD | 1992-10-05 | — | — | JP | disclosed |
| EP-0470668-A1 | A process for preparing enantiomers of compounds having muscarinic activity | MERCK SHARP & DOHME LTD. (GB) | 1992-02-12 | — | — | EP | disclosed |
| US-5073557-A | Cognition activators, stimulants of central muscarinic acetylc holine receptors | MERCK SHARP & DOHME LIMITED (GB) | 1991-12-17 | — | — | US | disclosed |
| US-5073557-A | Cognition activators, stimulants of central muscarinic acetylc holine receptors | MERCK SHARP & DOHME LIMITED (GB) | 1991-12-17 | — | — | US | disclosed |
| JP-H03135979-A | NEW SUBSTITUTED PYRAZINE, ITS FORMULATIONS AND MEDICINAL USE | MERCK SHARP & DOHME LTD | 1991-06-10 | — | — | JP | disclosed |
| EP-0416754-A2 | A novel substituted pyrazine, formulations thereof and use in medicine | MERCK SHARP & DOHME LTD. (GB) | 1991-03-13 | — | — | EP | disclosed |
| EP-0416754-A2 | A novel substituted pyrazine, formulations thereof and use in medicine | MERCK SHARP & DOHME LTD. (GB) | 1991-03-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060270698-A1 | Scopolamine for the treatment of depression and anxiety | CHRNA1, SLC18A3, CHRNB1 | CHRNA7 11/4885 |
| US-20140378501-A1 | SCOPOLAMINE FOR THE TREATMENT OF DEPRESSION AND ANXIETY | CHRNA1, CHRNA2, SLC18A3 | CHRNA7 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.